转移性结直肠癌免疫检查点抑制剂原发耐药与微卫星不稳定或错配修复缺陷状态误诊的关联
这项事后分析纳入38例局部实验室诊断为MSI或dMMR的mCRC患者,接受免疫检查点抑制剂后5例(13%)出现原发耐药,其中3例(60%)复评实为微卫星稳定或错配修复正常。局部实验室MSI或dMMR状态的阳性预测值为92.1%(95%CI 78.5%-98.0%);93例回顾性队列中误诊率为10%(n=9),阳性预测值90.3%(95%CI 82.4%-95.0%)。作者认为原发耐药主要源于MSI或dMMR状态误诊,建议治疗前常规联合免疫组化和聚合酶链反应检测,并需更大样本研究确认。
要点
- 38例局部诊断MSI或dMMR的mCRC中5例(13%)对免疫检查点抑制剂原发耐药。
- 5例原发耐药中3例(60%)复评实为微卫星稳定或错配修复正常。
- 局部MSI或dMMR检测阳性预测值92.1%(95%CI 78.5%-98.0%)。
核心结论
- mCRC中MSI或dMMR状态对免疫检查点抑制剂的原发耐药主要源于MSI或dMMR状态误诊。
- 作者认为需更大样本研究确认上述发现。
- 作者建议免疫检查点抑制剂治疗前常规联合免疫组化和聚合酶链反应方法检测MSI或dMMR状态。
研究设计与样本
- 事后分析,纳入单中心前瞻性队列38例mCRC患者,均由局部实验室诊断为MSI或dMMR,并于2015年1月1日至2016年12月31日进入免疫检查点抑制剂试验。
- 另设回顾性队列,纳入6家法国医院1998年1月1日至2016年12月31日诊断为MSI或dMMR的93例mCRC患者,均未接受免疫检查点抑制剂治疗。
- 原发耐药定义为免疫检查点抑制剂启动后6至8周按实体瘤疗效评价标准判定为疾病进展且无假性进展。
- 所有肿瘤样本复评dMMR采用针对MLH1、MSH2、MSH6和PMS2抗体的免疫组化,复评MSI采用五重标志物聚合酶链反应及HSP110 T17(HT17)重复序列检测。
- 主要结局为阳性预测值。
主要发现
- 38例患者(15例女性、23例男性;平均[标准差]年龄55.6[13.7]岁)中5例(13%)出现免疫检查点抑制剂原发耐药。
- 5例原发耐药肿瘤中3例(60%)复评显示为微卫星稳定或错配修复正常。
- 局部实验室评估MSI或dMMR状态的阳性预测值为92.1%(95%CI 78.5%-98.0%)。
- 93例回顾性队列(44例女性、49例男性;平均[标准差]年龄56.8[18.3]岁)中局部评估误诊MSI或dMMR状态10%(n=9),阳性预测值90.3%(95%CI 82.4%-95.0%)。
- 在免疫组化与五重聚合酶链反应结果不一致(即dMMR但微卫星稳定)的4例中,HT17检测确认了其中2例的MSI或dMMR状态。
关键数值与推荐
- 局部实验室评估MSI或dMMR状态的阳性预测值为92.1%(95%CI 78.5%-98.0%)。
- 回顾性队列中局部评估误诊MSI或dMMR状态10%(n=9),阳性预测值90.3%(95%CI 82.4%-95.0%)。
- 原发耐药5例中3例(60%)复评实为微卫星稳定或错配修复正常。
临床怎么用
- 作者建议免疫检查点抑制剂治疗前常规联合免疫组化和聚合酶链反应方法检测MSI或dMMR状态。
- 作者认为需更大样本研究确认上述发现。
局限性
- 作者指出需更大样本研究确认上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Primary resistance to immune checkpoint inhibitors is observed in 10% to 40% of patients with metastatic colorectal cancer (mCRC) displaying microsatellite instability (MSI) or defective mismatch repair (dMMR). OBJECTIVE: To investigate possible mechanisms underlying primary resistance to immune checkpoint inhibitors of mCRC displaying MSI or dMMR. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a single-center, prospective cohort included 38 patients with mCRC diagnosed as MSI or dMMR by local laboratories and entered into trials of immune checkpoint inhibitors between January 1, 2015, and December 31, 2016. The accuracy of MSI or dMMR status was also assessed in a retrospective cohort comprising 93 cases of mCRC that were diagnosed as MSI or dMMR between January 1, 1998, and December 31, 2016, in 6 French hospitals. Primary resistance of mCRC was defined as progressive disease according to Response Evaluation Criteria in Solid Tumors criteria, 6 to 8 weeks after initiation of immune checkpoint inhibitors, without pseudo-progression. All tumor samples were reassessed for dMMR status using immunohistochemistry with antibodies directed against MLH1, MSH2, MSH6, and PMS2, and for MSI using polymerase chain reaction with pentaplex markers and with the HSP110 T17 (HT17) repeat. MAIN OUTCOMES AND MEASURES: The primary outcome was positive predictive value. RESULTS: Among the 38 patients (15 women and 23 men; mean [SD] age, 55.6 [13.7] years) in the study with mCRC displaying MSI or dMMR, primary resistance to immune checkpoint inhibitors was observed in 5 individuals (13%). Reassessment of the status of MSI or dMMR revealed that 3 (60%) of these 5 resistant tumors were microsatellite stable or displayed proficient mismatch repair. The positive predictive value of MSI or dMMR status assessed by local laboratories was therefore 92.1% (95% CI, 78.5%-98.0%). In the retrospective cohort of 93 patients (44 women and 49 men; mean [SD] age, 56.8 [18.3] years) without immune checkpoint inhibitor treatment, misdiagnosis of the MSI or dMMR status by local assessment was 10% (n = 9), with a positive predictive value of 90.3% (95% CI, 82.4%-95.0%). Testing for MSI with the HT17 assay confirmed the MSI or dMMR status in 2 of 4 cases showing discrepant results between immunohistochemistry and pentaplex polymerase chain reaction (ie, dMMR but microsatellite stable). CONCLUSIONS AND RELEVANCE: Primary resistance of mCRC displaying MSI or dMMR to immune checkpoint inhibitors is due mainly to misdiagnosis of their MSI or dMMR status. Larger studies are required to confirm these findings. Microsatellite instability or dMMR status should be tested routinely using both immunohistochemistry and polymerase chain reaction methods prior to treatment with immune checkpoint inhibitors.
引用
- Cohen R, Hain E, Buhard O, et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol. 2019. PMID: 30452494. doi:10.1001/jamaoncol.2018.4942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。